Follow us:

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

February 28, 2006 at 10:25 AM

Nastech clears hurdle in generic race

The Food and Drug Administration cleared Nastech Pharmaceutical’s Bothell manufacturing facility to make a generic drug, but the company still faces regulatory and procedural hurdles before it can market the product.

The news today closes out a month of significant announcements for Nastech, which has seen its stock rise 15.4 percent since Feb. 1, closing Monday at $21.69, the highest level in nearly a decade.

It started with a partnership deal with Procter & Gamble worth up to $577 million. Then Nastech expanded its RNAi pipeline. Now the company is ready to manufacture calcitonin, a generic version of the osteoporosis drug Miacalcin, which it’s making with Par Pharmaceutical.

But there is still an unresolved citizen petition potentially delaying FDA action on approving Nastech’s generic drug, a situation detailed in this story. And Apotex applied for approval of its own generic calcitonin nasal spray before Nastech. That could mean Nastech would be delayed from marketing its generic for six months.

Comments | More in Biotechnology

COMMENTS

No personal attacks or insults, no hate speech, no profanity. Please keep the conversation civil and help us moderate this thread by reporting any abuse. See our Commenting FAQ.



The opinions expressed in reader comments are those of the author only, and do not reflect the opinions of The Seattle Times.


The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►
The Seattle Times

To keep reading, you need a subscription upgrade.

We hope you have enjoyed your complimentary access. For unlimited seattletimes.com access, please upgrade your digital subscription.

Call customer service at 1.800.542.0820 for assistance with your upgrade or questions about your subscriber status.

The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Activate Subscriber Account ►